Hyponatremia resident survival guide: Difference between revisions
Line 67: | Line 67: | ||
<br> | <br> | ||
==Therapeutic Approach== | ===Therapeutic Approach=== | ||
'''Initial Management''' | |||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | A01 | | | | | | | | | | {{familytree | | | | | | | | | A01 | | | | | | | | | | | | | | |A01=Symptomatic hyponatremia|A02=Asymptomatic hyponatremia }} | ||
{{familytree | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | {{familytree | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | | | | | }} | ||
{{familytree | | | | | B01 | | | | | | B02 | | | | | | | {{familytree | | | | | B01 | | | | | | B02 | | | | | | | | | | |B01=<div style="float: left; text-align: left; width:12em">Acute hyponatremia (< 48 hours) | ||
---- | ---- | ||
'''Goals of treatment:''' <br> ❑ Target sodium levels = 125-130 mEq/L<ref name="Gross-1998">{{Cite journal | last1 = Gross | first1 = P. | last2 = Reimann | first2 = D. | last3 = Neidel | first3 = J. | last4 = Döke | first4 = C. | last5 = Prospert | first5 = F. | last6 = Decaux | first6 = G. | last7 = Verbalis | first7 = J. | last8 = Schrier | first8 = RW. | title = The treatment of severe hyponatremia. | journal = Kidney Int Suppl | volume = 64 | issue = | pages = S6-11 | month = Feb | year = 1998 | doi = | PMID = 9475480 }}</ref> <br> ❑ Daily ↑ in sodium levels by 4-6 mmol/L </div>|B02=<div style="float: left; text-align: left; width:12em">Chronic hyponatremia | '''Goals of treatment:''' <br> ❑ Target sodium levels = 125-130 mEq/L<ref name="Gross-1998">{{Cite journal | last1 = Gross | first1 = P. | last2 = Reimann | first2 = D. | last3 = Neidel | first3 = J. | last4 = Döke | first4 = C. | last5 = Prospert | first5 = F. | last6 = Decaux | first6 = G. | last7 = Verbalis | first7 = J. | last8 = Schrier | first8 = RW. | title = The treatment of severe hyponatremia. | journal = Kidney Int Suppl | volume = 64 | issue = | pages = S6-11 | month = Feb | year = 1998 | doi = | PMID = 9475480 }}</ref> <br> ❑ Daily ↑ in sodium levels by 4-6 mmol/L </div>|B02=<div style="float: left; text-align: left; width:12em">Chronic hyponatremia | ||
---- | ---- | ||
'''Goals of treatment:''' <br> ❑ Target sodium levels = 125-130 mEq/L <br> ❑ Daily ↑ in sodium levels by 4-8 mmol/L if low risk of ODS <br> ❑ Daily ↑ in sodium levels by 4-6 mmol/L if high risk of ODS </div>}} | '''Goals of treatment:''' <br> ❑ Target sodium levels = 125-130 mEq/L <br> ❑ Daily ↑ in sodium levels by 4-8 mmol/L if low risk of ODS <br> ❑ Daily ↑ in sodium levels by 4-6 mmol/L if high risk of ODS </div>}} | ||
{{familytree | | | |,|-|^|-|.| | | |,|-|^|-|.| | | | | | {{familytree | | | |,|-|^|-|.| | | |,|-|^|-|.| | | | | | | | | | }} | ||
{{familytree | | | C01 | | C02 | | C03 | | C04 | | | | | {{familytree | | | C01 | | C02 | | C03 | | C04 | | | | | | | | |C01=Mild to moderate symptoms| C02=Severe symptoms|C03=Mild to moderate symptoms|C04=Severe symptoms }} | ||
{{familytree | | | |!| | | |!| | | |!| | | |!| | | | | | {{familytree | | | |!| | | |!| | | |!| | | |!| | | | | | | | | | }} | ||
{{familytree | | | D01 | | D02 | | D03 | | D04 | | | | | {{familytree | | | D01 | | D02 | | D03 | | D04 | | | | | | | | |D01=<div style="float: left; text-align: left">❑ Treat with 0.9% NaCl to achieve target sodium levels or treat with [[Hyponatremia medical therapy#Vaptan Drugs|vaptans]]</div>|D02=<div style="float: left; text-align: left">❑ Treat with 3% NaCl to begin with (100 ml infused over 10 minutes and repeated once if needed) <br> ❑ Transition to 0.9% NaCl/[[Hyponatremia medical therapy#Vaptan Drugs|vaptans]] at sodium levels > 125 mEq/L </div>|D03=<div style="float: left; text-align: left">❑ Treat with 0.9% NaCl to achieve target sodium levels or treat with [[Hyponatremia medical therapy#Vaptan Drugs|vaptans]]</div>|D04=<div style="float: left; text-align: left">❑ Treat with 3% NaCl to begin with <br> ❑ Achieve 1st day target in 1st 6 hours and withhold any more fluids for the day <br> ❑ Transition to 0.9% NaCl/[[Hyponatremia medical therapy#Vaptan Drugs|vaptans]] at sodium levels > 125 mEq/L</div>}} | ||
{{familytree | | | |`|-|-|-|^|-|v|-|^|-|-|-|'| | | | | | {{familytree | | | |`|-|-|-|^|-|v|-|^|-|-|-|'| | | | | | | | | | }} | ||
{{familytree | | | | | | | | | E01 | | | | | | | | | | | {{familytree | | | | | | | | | E01 | | | | | | | | | | | | | | |E01=<div style="float: left; text-align: left; width:20em">Administer [[Hyponatremia medical therapy#Vaptan Drugs|vaptans]] (vasopressin receptor antagonists): Contraindicated for hypovolemic hyponatremia | ||
---- | ---- | ||
'''[[Conivaptan]]:''' <br> ❑ IV 20 mg loading dose over 30 minutes, followed by a continuous infusion of 20 mg/day <br> ❑ Max infusion rate 40 mg/day <br> ❑ Duration of treatment 4 days or target sodium level <br> ❑ Monitor with sodium levels every 6-8 hours | '''[[Conivaptan]]:''' <br> ❑ IV 20 mg loading dose over 30 minutes, followed by a continuous infusion of 20 mg/day <br> ❑ Max infusion rate 40 mg/day <br> ❑ Duration of treatment 4 days or target sodium level <br> ❑ Monitor with sodium levels every 6-8 hours | ||
Line 91: | Line 91: | ||
: Increase in sodium <5 mmol/L in last 24 hours <br> | : Increase in sodium <5 mmol/L in last 24 hours <br> | ||
❑ Monitor with sodium levels every 6-8 hours </div> }} | ❑ Monitor with sodium levels every 6-8 hours </div> }} | ||
{{familytree | {{familytree/end}} | ||
{{familytree | | | | | | | | | F01 | | |||
'''Additional Management''' | |||
Shown below is an algorithm depicting the management of symptomatic and asymptomatic hyponatremia based on underlying etiology. | |||
{{familytree/start}} | |||
{{familytree | | | | | | | | | F01 | | | | | | | | | | | | | | |F01=Etiology based management }} | |||
{{familytree | | | |,|-|-|-|-|-|+|-|-|-|-|-|.| | | | | | | | }} | {{familytree | | | |,|-|-|-|-|-|+|-|-|-|-|-|.| | | | | | | | }} | ||
{{familytree | | | G01 | | | | G02 | | | | G03 | | | | | | | | |G01= '''[[Hypovolemia]]''' <br>| G02= '''[[fluid balance|Euvolemia]]'''| G03= '''[[Hypervolemia]]''' }} | {{familytree | | | G01 | | | | G02 | | | | G03 | | | | | | | | |G01= '''[[Hypovolemia]]''' <br>| G02= '''[[fluid balance|Euvolemia]]'''| G03= '''[[Hypervolemia]]''' }} | ||
Line 127: | Line 131: | ||
{{familytree/end}} | {{familytree/end}} | ||
<span style="font-size:85%">'''ADH''': Anti diuretic hormone; '''SIADH''': Syndrome of inappropriate antidiuretic hormone secretion; '''NaCl''': Sodium chloride; '''LFT''': Liver function test;'''IV''': Intravenous; '''PO''': Per oral; '''ECF''':Extra cellular fluid; '''HPE''':History and physical examination; '''ODS:''' Osmotic demyelination syndrome </span> | |||
==Do's== | ==Do's== |
Revision as of 18:45, 4 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]
Definitions
Hyponatremia is defined as a serum sodium concentration < 135 mEq/L.[1]
Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Severe hyponatremia ( <115 mEq/L) is by itself life threatening and should be treated as such irrespective of the cause.[2]
Common Causes
Causes of hyponatremia are classified based on patients volume status as follows:
Hypovolemic hyponatremia:
- Cerebral salt wasting syndrome
- Adrenal failure[3][4]
- Thiazide diuretics[5]
- Vomiting & diarrhea treated with free water replacement
Euvolemic hyponatremia:
- SIADH
- Primary polydipsia
- Exercise associated hyponatremia
- Nephrogenic syndrome of inappropriate antidiuresis
- Glucocorticoid deficiency
- Hypothyroidism
- Low solute intake
Hypervolemic hyponatremia:
Management
Shown below is an algorithm depicting management of hyponatremia based on Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations (2013)[7]
Diagnostic Approach
Characterize the symptoms: ❑ Nausea and vomiting ❑ Headache ❑ Confusion ❑ Lethargy, fatigue, loss of appetite ❑ Restlessness and irritability ❑ Muscle weakness, spasms, cramps ❑ Seizures ❑ Decreased consciousness or coma[8] Hyponatremic encephalopathy: (sodium < 115 meq/L) ❑ Decorticate or decerebrate posturing ❑ Respiratory arrest ❑ Non-cardiogenic pulmonary edema | |||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Orthostatic vital signs ❑ Mental status examination (low score) ❑ Jugular venous pressure ↑/↓ ❑ Peripheral edema | |||||||||||||||||||||||||||||||||||||||||
Check labs: ❑ Plasma osmolality ❑ Urine osmolality ❑ Urinary sodium concentration ❑ Serum uric acid/Creatinine ❑ Thyroid stimulating hormone (TSH) ❑ Serum cortisol level ❑ Serum proteins/triglyceride ❑ Random blood sugar | |||||||||||||||||||||||||||||||||||||||||
Consider alternative diagnosis: ❑ Adrenal crisis ❑ Alcoholism ❑ Hypothyroidism ❑ Pulmonary/cardiogenic edema | |||||||||||||||||||||||||||||||||||||||||
❑ Check serum osmolality Serum osmolality (mmol/kg) = (2 x serum sodium concentration) + (serum glucose concentration/18) + (blood urea nitrogen/2.8) | |||||||||||||||||||||||||||||||||||||||||
280-295 mOsm/kg - Isotonic hyponatremia | < 280 mOsm/kg - Hypotonic hyponatremia | > 295 mOsm/kg - Hypertonic hypernatremia | |||||||||||||||||||||||||||||||||||||||
Pseudohyponatremia | Assess volume status | Hyperglycemia Mannitol infusion | |||||||||||||||||||||||||||||||||||||||
Hypovolemia | Euvolemia | Hypervolemia | |||||||||||||||||||||||||||||||||||||||
Urine sodium levels | Urine sodium levels | Urine sodium levels | |||||||||||||||||||||||||||||||||||||||
>20 mEq/L | ≤ 20 mEq/L | >20 mEq/L | >20 mEq/L | ≤ 20 mEq/L | |||||||||||||||||||||||||||||||||||||
❑ Vomiting & diarrhea treated with free water replacement | ❑ SIADH ❑ Primary polydipsia ❑ Exercise associated hyponatremia ❑ Nephrogenic syndrome of inappropriate antidiuresis ❑ Glucocorticoid deficiency ❑ Hypothyroidism ❑ Low solute intake | ||||||||||||||||||||||||||||||||||||||||
Therapeutic Approach
Initial Management
Symptomatic hyponatremia | |||||||||||||||||||||||||||||||||||||||||||||||||||
Acute hyponatremia (< 48 hours)
Goals of treatment: ❑ Target sodium levels = 125-130 mEq/L[9] ❑ Daily ↑ in sodium levels by 4-6 mmol/L | Chronic hyponatremia
Goals of treatment: ❑ Target sodium levels = 125-130 mEq/L ❑ Daily ↑ in sodium levels by 4-8 mmol/L if low risk of ODS ❑ Daily ↑ in sodium levels by 4-6 mmol/L if high risk of ODS | ||||||||||||||||||||||||||||||||||||||||||||||||||
Mild to moderate symptoms | Severe symptoms | Mild to moderate symptoms | Severe symptoms | ||||||||||||||||||||||||||||||||||||||||||||||||
❑ Treat with 0.9% NaCl to achieve target sodium levels or treat with vaptans | ❑ Treat with 3% NaCl to begin with (100 ml infused over 10 minutes and repeated once if needed) ❑ Transition to 0.9% NaCl/vaptans at sodium levels > 125 mEq/L | ❑ Treat with 0.9% NaCl to achieve target sodium levels or treat with vaptans | ❑ Treat with 3% NaCl to begin with ❑ Achieve 1st day target in 1st 6 hours and withhold any more fluids for the day ❑ Transition to 0.9% NaCl/vaptans at sodium levels > 125 mEq/L | ||||||||||||||||||||||||||||||||||||||||||||||||
Administer vaptans (vasopressin receptor antagonists): Contraindicated for hypovolemic hyponatremia
Conivaptan: Tolvapatan: (Use only if sodium < 125 mEq/L or pt. symptomatic)
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Management Shown below is an algorithm depicting the management of symptomatic and asymptomatic hyponatremia based on underlying etiology.
Etiology based management | |||||||||||||||||||||||||||||||||||||||||||||||||||
Hypovolemia | Euvolemia | Hypervolemia | |||||||||||||||||||||||||||||||||||||||||||||||||
Urine sodium level > 20 mEq/L
Cerebral salt wasting syndrome: Adrenal failure: Thiazide like diuretics: ❑ Stop thiazide diuretics ❑ Monitor rate of rise of sodium ❑ Monitor urine osmolality & volume to detect hypercorrection ❑ Follow K+ levels, as they may drop with therapy | Urine sodium level ≤ 20 mEq/L
Gastrointestinal losses: ❑ Correct K+ levels as appropriate ❑ Administer bicarbonate if acidosis develops ❑ Start antiemetics and specific therapy as indicated | Urine sodium level > 20 mEq/L
❑ SIADH: Nephrogenic syndrome of inappropriate antidiuresis: Hypothyroidism: Glucocorticoid def.: Exercise associated hyponatremia: Low solute intake: Primary polydipsia: ❑ Implement free water restriction | Urine sodium level > 20 mEq/L
Acute kidney injury: ❑ Implement free water restriction (mainstay) ❑ Vaptans are less effective | Urine sodium level ≤ 20 mEq/L
Heart failure: Liver cirrhosis: ❑ Use tolvaptan restrictively based on LFT's | |||||||||||||||||||||||||||||||||||||||||||||||
ADH: Anti diuretic hormone; SIADH: Syndrome of inappropriate antidiuretic hormone secretion; NaCl: Sodium chloride; LFT: Liver function test;IV: Intravenous; PO: Per oral; ECF:Extra cellular fluid; HPE:History and physical examination; ODS: Osmotic demyelination syndrome
Do's
- Categorize hyponatremia based on volume status, use history, physical examination and labs.
- Do the following to prevent over correction of sodium levels:
- Replace water losses or administer desmopressin after correction by 6-8 mmol/L during the first 24 hours of therapy.
- Withhold the next dose of vaptans if the correction is >8 mmol/L.
- Consider therapeutic re-lowering of serum sodium if correction exceeds therapeutic limits.
- Consider administration of high-dose glucocorticoids (eg, dexamethasone, 4 mg every 6 hours) for 24-48 hours following the excessive correction.
- Follow these steps to re lower serum sodium:
- Administer desmopressin to prevent further water losses: 2-4 mg every 8 hours parenterally.
- Replace water orally or as 5% dextrose in water intravenously: 3 mL/kg/h.
- Recheck serum sodium hourly and continue therapy infusion until serum sodium is reduced to goal.
- Initiate vaptans treatment only in hospital setting, so as to regularly monitor serum sodium levels.
- Fluid restriction:
- Restrict all intake that is consumed by drinking, not just water.
- Aim for a fluid restriction that is 500 mL/d below the 24-hour urine volume.
- Do not restrict sodium or protein intake unless indicated.
- Gastrointestinal losses:
- Measure urine chloride, if vomiting is present to confirm the presence of solute and volume depletion.
- Treat typically as a chronic hyponatremia.
- Thiazide diuretic induce:
- Treat typically as chronic hyponatremia.
- Be vary of rapid correction.
- Serially follow changes in urine osmolality together with urine volume.
- Measure serum sodium every 6 hours to begin with.
- Adjust potassium levels in fluids as needed.
Dont's
- Do not use to treat hypovolemic hyponatremia.
- Do not use in conjunction with other treatments for hyponatremia.
- Do not use immediately after cessation of other treatments for hyponatremia, particularly 3% NaCl.
- Do not use for severe, symptomatic hyponatremia, as 3% NaCl provides a quicker and more certain correction of serum sodium than vaptans.
- Do not use Isotonic normal saline as primary therapy for SIADH.
References
- ↑ Laczi, F. (2008). "[Etiology, diagnostics and therapy of hyponatremias]". Orv Hetil. 149 (29): 1347–54. doi:10.1556/OH.2008.28409. PMID 18617466. Unknown parameter
|month=
ignored (help) - ↑ Clayton, JA.; Le Jeune, IR.; Hall, IP. (2006). "Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome". QJM. 99 (8): 505–11. doi:10.1093/qjmed/hcl071. PMID 16861720. Unknown parameter
|month=
ignored (help) - ↑ Schmitz, PH.; de Meijer, PH.; Meinders, AE. (2001). "Hyponatremia due to hypothyroidism: a pure renal mechanism". Neth J Med. 58 (3): 143–9. PMID 11246114. Unknown parameter
|month=
ignored (help) - ↑ Macaron, C.; Famuyiwa, O. (1978). "Hyponatremia of hypothyroidism. Appropriate suppression of antidiuretic hormone levels". Arch Intern Med. 138 (5): 820–2. PMID 417689. Unknown parameter
|month=
ignored (help) - ↑ Leung, AA.; Wright, A.; Pazo, V.; Karson, A.; Bates, DW. (2011). "Risk of thiazide-induced hyponatremia in patients with hypertension". Am J Med. 124 (11): 1064–72. doi:10.1016/j.amjmed.2011.06.031. PMID 22017784. Unknown parameter
|month=
ignored (help) - ↑ Oren, RM. (2005). "Hyponatremia in congestive heart failure". Am J Cardiol. 95 (9A): 2B–7B. doi:10.1016/j.amjcard.2005.03.002. PMID 15847851. Unknown parameter
|month=
ignored (help) - ↑ Verbalis, JG.; Goldsmith, SR.; Greenberg, A.; Korzelius, C.; Schrier, RW.; Sterns, RH.; Thompson, CJ. (2013). "Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations". Am J Med. 126 (10 Suppl 1): S1–42. doi:10.1016/j.amjmed.2013.07.006. PMID 24074529. Unknown parameter
|month=
ignored (help) - ↑ "Sign In" (PDF). Retrieved 28 January 2014.
- ↑ Gross, P.; Reimann, D.; Neidel, J.; Döke, C.; Prospert, F.; Decaux, G.; Verbalis, J.; Schrier, RW. (1998). "The treatment of severe hyponatremia". Kidney Int Suppl. 64: S6–11. PMID 9475480. Unknown parameter
|month=
ignored (help)